摘要
目的:评价米氮平与文拉法辛治疗抑郁症的疗效和不良反应。方法:将符合CCMD-3诊断标准的84例抑郁症住院和门诊患者,随机平分为两组,分别予米氮平和文拉法辛治疗,疗程8周。用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床疗效总评量表的病情严重程度(CGI-S1)和副反应量表(TESS)评定疗效和不良反应。结果:米氮平与文拉法辛对抑郁症疗效接近,但前者起效更快,不良反应少于后者。结论:米氮平是一种安全、有效的新一代抗抑郁药,可作为治疗抑郁症的第一线药物使用。
Objective：To compare efficacy and side effects between Mirtazapine vs Venlafaxine in the treatment of depression. Methods：84 inpatients and outpatients with a diagnosis of depression according to CCMD -3 were involved in this study, they were randomly assigned to the Mirtazapine group （n = 42） and the Venlafaxine group （n = 42） for 8 weeks. Effects and side reactions were evaluated with HAMD, HAMA, CGI -SI and TESS before and after the treatment. Results： Findings indicated that efficacy of Mirtazapine was similar to than of Venlafaxine, however Mirtazapine took effect more quickly and its side effects were less than Venlafaxine. Conclusions： Both Mirtazapine and Venlafaxine have better efficacy and milder side effect in the treatment of depression. Mirtazapine is an effective and safe antidepressant. It is suggested that Mirtazapine could be used as a first - line antidepressant in the treatment of depression.
出处
《中国民康医学》
2007年第23期1017-1018,共2页
Medical Journal of Chinese People’s Health
关键词
米氮平
文拉法辛
抑郁症
对照研究
Mirtazapine
Venlafaxine
Depression
Comparative study
